{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T06:27:26Z","timestamp":1789712846133,"version":"4.0.1"},"reference-count":53,"publisher":"Public Library of Science (PLoS)","issue":"5","license":[{"start":{"date-parts":[[2017,5,3]],"date-time":"2017-05-03T00:00:00Z","timestamp":1493769600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["HEO-115694"],"award-info":[{"award-number":["HEO-115694"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000156","name":"Fonds de Recherche du Qu\u00e9bec - Sant\u00e9","doi-asserted-by":"publisher","award":["n\/a"],"award-info":[{"award-number":["n\/a"]}],"id":[{"id":"10.13039\/501100000156","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["FDN-143270"],"award-info":[{"award-number":["FDN-143270"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002879","name":"Canadian HIV Trials Network, Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["CTN-222"],"award-info":[{"award-number":["CTN-222"]}],"id":[{"id":"10.13039\/501100002879","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0176282","type":"journal-article","created":{"date-parts":[[2017,5,3]],"date-time":"2017-05-03T17:48:22Z","timestamp":1493833702000},"page":"e0176282","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":9,"title":["A prognostic model for development of significant liver fibrosis in HIV-hepatitis C co-infection"],"prefix":"10.1371","volume":"12","author":[{"given":"Nasheed","family":"Moqueet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Kanagaratham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. John","family":"Gill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Hull","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"Walmsley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danuta","family":"Radzioch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahar","family":"Saeed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert W.","family":"Platt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina B.","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the Canadian Co-infection Cohort Study (CTN 222)","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2017,5,3]]},"reference":[{"issue":"12","key":"ref1","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1016\/j.cgh.2010.08.024","article-title":"Liver Disease in the HIV-Infected Individual","volume":"8","author":"JC Price","year":"2010","journal-title":"Clinical gastroenterology and hepatology: the official clinical practice journal of the American Gastroenterological Association"},{"issue":"6","key":"ref2","doi-asserted-by":"crossref","first-page":"369","DOI":"10.7326\/M13-1829","article-title":"Hepatic decompensation in antiretroviral-treated patients co-infected with HIV and hepatitis C virus compared with hepatitis C virus-monoinfected patients: a cohort study","volume":"160","author":"V Lo Re 3rd","year":"2014","journal-title":"Annals of internal medicine"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"e30","DOI":"10.1017\/S1462399408000847","article-title":"Cellular and molecular interactions in coinfection with hepatitis C virus and human immunodeficiency virus","volume":"10","author":"B Roe","year":"2008","journal-title":"Expert reviews in molecular medicine"},{"issue":"4","key":"ref4","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1002\/hep.510300409","article-title":"Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group","volume":"30","author":"Y Benhamou","year":"1999","journal-title":"Hepatology"},{"issue":"4","key":"ref5","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1086\/321909","article-title":"Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis","volume":"33","author":"CS Graham","year":"2001","journal-title":"Clinical infectious diseases: an official publication of the Infectious Diseases Society of America"},{"key":"ref6","article-title":"HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C","year":"2015"},{"issue":"1","key":"ref7","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.jhep.2015.04.006","article-title":"EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis","volume":"63","year":"2015","journal-title":"Journal of hepatology"},{"issue":"8","key":"ref8","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1155\/2014\/140864","article-title":"With all the new treatment regimens, complete elimination of hepatitis C virus in Canada is a possibility! But when will Canadians have access these drugs?","volume":"28","author":"KM Peltekian","year":"2014","journal-title":"Canadian journal of gastroenterology & hepatology"},{"issue":"6","key":"ref9","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1155\/2014\/251989","article-title":"CIHR Canadian HIV Trials Network Co-Infection and Concurrent Diseases Core: Updated Canadian guidelines for the treatment of hepatitis C infection in HIV-hepatitis C coinfected adults","volume":"25","author":"M Hull","year":"2014","journal-title":"The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale \/ AMMI Canada"},{"key":"ref10","unstructured":"British Columbia PharmaCare Information for Prescribers: Determining fibrosis stage for the treatment of chronic hepatitis C. British Columbia PharmaCare, Division MBaPS; October 2014."},{"issue":"4","key":"ref11","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1111\/j.1478-3231.2011.02449.x","article-title":"Genes and hepatitis C: susceptibility, fibrosis progression and response to treatment","volume":"31","author":"M Romero-Gomez","year":"2011","journal-title":"Liver international: official journal of the International Association for the Study of the Liver"},{"issue":"1","key":"ref12","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1053\/gast.2003.50018","article-title":"Progression of fibrosis in chronic hepatitis C","volume":"124","author":"MG Ghany","year":"2003","journal-title":"Gastroenterology"},{"issue":"11","key":"ref13","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1111\/j.1365-2893.2011.01481.x","article-title":"Role of hepatitis C virus genotype 3 in liver fibrosis progression\u2014a systematic review and meta-analysis","volume":"18","author":"A Probst","year":"2011","journal-title":"Journal of viral hepatitis"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"6422","DOI":"10.1038\/ncomms7422","article-title":"Interferon-lambda rs12979860 genotype and liver fibrosis in viral and non-viral chronic liver disease","volume":"6","author":"M Eslam","year":"2015","journal-title":"Nature communications"},{"issue":"1","key":"ref15","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1093\/infdis\/jiw088","article-title":"Responder Interferon lambda Genotypes Are Associated With Higher Risk of Liver Fibrosis in HIV-Hepatitis C Virus Coinfection","volume":"214","author":"N Moqueet","year":"2016","journal-title":"The Journal of infectious diseases"},{"issue":"5","key":"ref16","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1093\/ije\/dyp297","article-title":"Cohort profile: the Canadian HIV-hepatitis C co-infection cohort study","volume":"39","author":"MB Klein","year":"2010","journal-title":"International journal of epidemiology"},{"issue":"6","key":"ref17","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1111\/j.1468-1293.2005.00330.x","article-title":"Validation of a simple model for predicting liver fibrosis in HIV\/hepatitis C virus-coinfected patients","volume":"6","author":"H Al-Mohri","year":"2005","journal-title":"HIV medicine"},{"issue":"4","key":"ref18","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1097\/QAI.0b013e318030ff8e","article-title":"Evaluating liver fibrosis progression and the impact of antiretroviral therapy in HIV and hepatitis C coinfection using a noninvasive marker","volume":"44","author":"H Al-Mohri","year":"2007","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"3","key":"ref19","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1136\/gut.2005.065904","article-title":"Prediction of liver fibrosis in human immunodeficiency virus\/hepatitis C virus coinfected patients by simple non-invasive indexes","volume":"55","author":"J Macias","year":"2006","journal-title":"Gut"},{"issue":"1","key":"ref20","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1111\/j.1468-1293.2010.00836.x","article-title":"Combined use of aspartate aminotransferase, platelet count and matrix metalloproteinase 2 measurements to predict liver fibrosis in HIV\/hepatitis C virus-coinfected patients","volume":"12","author":"J Macias","year":"2011","journal-title":"HIV medicine"},{"issue":"9262","key":"ref21","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1016\/S0140-6736(00)04258-6","article-title":"Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study","volume":"357","author":"F Imbert-Bismut","year":"2001","journal-title":"Lancet"},{"issue":"10","key":"ref22","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1373\/clinchem.2005.048389","article-title":"Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis C infection","volume":"51","author":"LA Adams","year":"2005","journal-title":"Clinical chemistry"},{"issue":"4","key":"ref23","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1053\/jhep.2002.36128","article-title":"Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model","volume":"36","author":"X Forns","year":"2002","journal-title":"Hepatology"},{"issue":"3","key":"ref24","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.jhep.2010.03.022","article-title":"Common variation of IL28 affects gamma-GTP levels and inflammation of the liver in chronically infected hepatitis C virus patients","volume":"53","author":"H Abe","year":"2010","journal-title":"Journal of hepatology"},{"issue":"11","key":"ref25","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1093\/infdis\/jir113","article-title":"Influence of interleukin-28B single-nucleotide polymorphisms on progression to liver cirrhosis in human immunodeficiency virus-hepatitis C virus-coinfected patients receiving antiretroviral therapy","volume":"203","author":"P Barreiro","year":"2011","journal-title":"The Journal of infectious diseases"},{"issue":"1","key":"ref26","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1002\/hep.25598","article-title":"Association between interleukin-28B-related genetic variants and liver histopathology differs between hepatitis C virus genotypes","volume":"56","author":"K Rembeck","year":"2012","journal-title":"Hepatology"},{"issue":"54","key":"ref27","doi-asserted-by":"publisher","first-page":"S539","DOI":"10.1016\/S0168-8278(11)61363-9","article-title":"IL28B polymorphisms linked to poor response to treatment are associated with low necroinflammatory activity and slow fibrosis progression in HCV genotype non1-infected patients","volume":"54","author":"P Bochud","year":"2011","journal-title":"Journal of hepatology"},{"issue":"5","key":"ref28","doi-asserted-by":"publisher","first-page":"7213","DOI":"10.3390\/ijms15057213","article-title":"The association of IL28B genotype with the histological features of chronic hepatitis C is HCV genotype dependent","volume":"15","author":"R D'Ambrosio","year":"2014","journal-title":"International journal of molecular sciences"},{"issue":"2","key":"ref29","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1002\/hep.25647","article-title":"Dysregulation of innate immunity in hepatitis C virus genotype 1 IL28B-unfavorable genotype patients: impaired viral kinetics and therapeutic response","volume":"56","author":"S Naggie","year":"2012","journal-title":"Hepatology"},{"issue":"9","key":"ref30","doi-asserted-by":"publisher","first-page":"e1001092","DOI":"10.1371\/journal.pmed.1001092","article-title":"IL28B,HLA-C, and KIR Variants Additively Predict Response to Therapy in Chronic Hepatitis C Virus Infection in a European Cohort: A Cross-Sectional Study","volume":"8","author":"V Suppiah","year":"2011","journal-title":"PLoS medicine"},{"issue":"1","key":"ref31","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1128\/CMR.00050-12","article-title":"Microbial translocation in the pathogenesis of HIV infection and AIDS","volume":"26","author":"G Marchetti","year":"2013","journal-title":"Clinical microbiology reviews"},{"issue":"11","key":"ref32","doi-asserted-by":"publisher","first-page":"995","DOI":"10.2174\/1381612024606983","article-title":"Biological and clinical significance of endotoxemia in the course of hepatitis C virus infection","volume":"8","author":"L Caradonna","year":"2002","journal-title":"Current pharmaceutical design"},{"issue":"3","key":"ref33","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1046\/j.1440-1746.2003.02930.x","article-title":"Clinical use of hyaluronic acid as a predictor of fibrosis change in hepatitis C","volume":"18","author":"K Patel","year":"2003","journal-title":"Journal of gastroenterology and hepatology"},{"issue":"1","key":"ref34","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.jhep.2005.02.025","article-title":"Prediction of hepatic fibrosis in HIV\/HCV co-infected patients using serum fibrosis markers: the SHASTA index","volume":"43","author":"TB Kelleher","year":"2005","journal-title":"Journal of hepatology"},{"issue":"3","key":"ref35","doi-asserted-by":"publisher","first-page":"6496","DOI":"10.3390\/ijms16036496","article-title":"Favourable IFNL3 genotypes are associated with spontaneous clearance and are differentially distributed in Aboriginals in Canadian HIV-hepatitis C co-infected individuals","volume":"16","author":"N Moqueet","year":"2015","journal-title":"International journal of molecular sciences"},{"issue":"12","key":"ref36","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1016\/S0895-4356(99)00102-X","article-title":"Analysis of case-cohort designs","volume":"52","author":"WE Barlow","year":"1999","journal-title":"Journal of clinical epidemiology"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"b604","DOI":"10.1136\/bmj.b604","article-title":"Prognosis and prognostic research: Developing a prognostic model","volume":"338","author":"P Royston","year":"2009","journal-title":"BMJ"},{"issue":"3","key":"ref38","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1177\/1536867X1001000303","article-title":"Comparing the predictive powers of survival models using Harrell's C or Somers' D","volume":"10","author":"RB Newson","year":"2010","journal-title":"Stata Journal"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1186\/1471-2288-13-113","article-title":"Derivation and assessment of risk prediction models using case-cohort data","volume":"13","author":"J Sanderson","year":"2013","journal-title":"BMC medical research methodology"},{"issue":"4","key":"ref40","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/BF00127305","article-title":"A method for checking regression models in survival analysis based on the risk score","volume":"2","author":"JK Gronnesby","year":"1996","journal-title":"Lifetime data analysis"},{"issue":"1","key":"ref41","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1177\/1536867X1501500116","article-title":"Tools for checking calibration of a Cox model in external validation: Prediction of population-averaged survival curves based on risk groups","volume":"15","author":"P Royston","year":"2015","journal-title":"Stata Journal"},{"issue":"2","key":"ref42","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1002\/sim.2929","article-title":"Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond","volume":"27","author":"MJ Pencina","year":"2008","journal-title":"Statistics in medicine"},{"issue":"1","key":"ref43","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1002\/hep.27069","article-title":"Evolution of noninvasive tests of liver fibrosis is associated with prognosis in patients with chronic hepatitis C","volume":"60","author":"J Vergniol","year":"2014","journal-title":"Hepatology"},{"issue":"13","key":"ref44","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1002\/sim.4130","article-title":"Multiple imputation analysis of case-cohort studies","volume":"30","author":"H Marti","year":"2011","journal-title":"Statistics in medicine"},{"issue":"1","key":"ref45","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.cyto.2007.05.013","article-title":"Chemokines in hepatitis C virus infection: pathogenesis, prognosis and therapeutics","volume":"39","author":"O Wald","year":"2007","journal-title":"Cytokine"},{"issue":"1","key":"ref46","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1373\/clinchem.2007.096529","article-title":"Statistical evaluation of prognostic versus diagnostic models: beyond the ROC curve","volume":"54","author":"NR Cook","year":"2008","journal-title":"Clinical chemistry"},{"issue":"3","key":"ref47","doi-asserted-by":"publisher","first-page":"ofv109","DOI":"10.1093\/ofid\/ofv109","article-title":"Predicting Risk of End-Stage Liver Disease in Antiretroviral-Treated Human Immunodeficiency Virus\/Hepatitis C Virus-Coinfected Patients","volume":"2","author":"V Lo Re","year":"2015","journal-title":"Open Forum Infectious Diseases"},{"issue":"4","key":"ref48","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1097\/QAD.0b013e32835b8c7f","article-title":"An internationally generalizable risk index for mortality after one year of antiretroviral therapy","volume":"27","author":"JP Tate","year":"2013","journal-title":"AIDS (London, England)"},{"issue":"3","key":"ref49","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1002\/hep.21563","article-title":"The model for end-stage liver disease (MELD)","volume":"45","author":"PS Kamath","year":"2007","journal-title":"Hepatology"},{"issue":"2","key":"ref50","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1001\/jama.2011.1966","article-title":"Prognostic indices for older adults: a systematic review","volume":"307","author":"LC Yourman","year":"2012","journal-title":"JAMA: the journal of the American Medical Association"},{"issue":"2","key":"ref51","doi-asserted-by":"publisher","first-page":"122","DOI":"10.7326\/M13-1522","article-title":"Net reclassification improvement: computation, interpretation, and controversies: a literature review and clinician's guide","volume":"160","author":"MJ Leening","year":"2014","journal-title":"Annals of internal medicine"},{"issue":"21","key":"ref52","doi-asserted-by":"publisher","first-page":"2454","DOI":"10.1001\/archinte.165.21.2454","article-title":"When is a new prediction marker useful? A consideration of lipoprotein-associated phospholipase A2 and C-reactive protein for stroke risk","volume":"165","author":"P Greenland","year":"2005","journal-title":"Archives of internal medicine"},{"issue":"4","key":"ref53","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1002\/sim.4067","article-title":"Multiple imputation using chained equations: Issues and guidance for practice","volume":"30","author":"IR White","year":"2011","journal-title":"Statistics in medicine"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0176282","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T04:07:42Z","timestamp":1750219662000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0176282"}},"subtitle":[],"editor":[{"given":"Jason","family":"Blackard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2017,5,3]]},"references-count":53,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2017,5,3]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0176282","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,3]]}}}